TokenPost·
Trevi Expects Q1 2027 Start for Phase 2 Non-IPF ILD-Related Chronic Cough Trial
Trevi’s $299.4 million in cash, cash equivalents and marketable securities is expected to support key programs into 2030.
More news
- TokenPostOndo Plans to Offer Tokenized Anthropic Shares on IPO Day
- TokenPostAmeresco Expects Five Data Center Projects to Enter Contracted Backlog in 12 to 18 Months
- Bitcoin.com NewsUS Targets $456K in Crypto Allegedly Tied to Dating Site, Facebook Fraud
- TokenPostWLFI Says USD1 Revenue May Fund Token Buybacks After Costs
- TokenPostGrayscale Highlights NYSE Selection of Avalanche for Settlement
- TokenPostClaude Fable 5.2 Leads AA-3D Leaderboard With 1,271 Elo